Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design

Abstract Aims In univentricular hearts, selective lung vasodilators such as phosphodiesterase type 5 (PDE5) inhibitors would decrease pulmonary resistance and improve exercise tolerance. However, the level of evidence for the use of PDE5 inhibitors in patients with a single ventricle (SV) remains li...

Full description

Bibliographic Details
Main Authors: Pascal Amedro, Arthur Gavotto, Hamouda Abassi, Marie‐Christine Picot, Stefan Matecki, Sophie Malekzadeh‐Milani, Marilyne Levy, Magalie Ladouceur, Caroline Ovaert, Philippe Aldebert, Jean‐Benoit Thambo, Alain Fraisse, Marc Humbert, Sarah Cohen, Alban‐Elouen Baruteau, Clement Karsenty, Damien Bonnet, Sebastien Hascoet, SV‐INHIBITION study investigators
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:ESC Heart Failure
Subjects:
Congenital heart defect
Single ventricle
Pulmonary hypertension
Sildenafil
Pulmonary vasodilator
Exercise capacity
Online Access:https://doi.org/10.1002/ehf2.12630

Internet

https://doi.org/10.1002/ehf2.12630

Similar Items